VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
-9.21%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$617M
AUM Growth
+$617M
(-16%)
Cap. Flow
+$4.92M
Cap. Flow
% of AUM
0.8%
Top 10 Holdings %
Top 10 Hldgs %
74.33%
Holding
32
New
6
Increased
3
Reduced
2
Closed
5
Top Buys
| 1 |
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
|
$12.2M |
| 2 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$8.22M |
| 3 |
PRVB
Provention Bio, Inc. Common Stock
PRVB
|
$8.19M |
| 4 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
$5.21M |
| 5 |
Altimmune
ALT
|
$4.63M |
Top Sells
| 1 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
$13.7M |
| 2 |
Olema Pharmaceuticals
OLMA
|
$7.64M |
| 3 |
CVRx
CVRX
|
$6.52M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$6.42M |
| 5 |
AKYA
Akoya BioSciences
AKYA
|
$6.12M |
Sector Composition
| 1 | Healthcare | 95.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
JBIO
26
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $2.77M | 0.45% |
+151,037
| New | +$2.77M |
|
27
Savara
SVRA
$591M
| $2.5M | 0.4% |
+1,905,265
| New | +$2.5M |
|
|
AKYA
28
DELISTED
Akoya BioSciences
AKYA
| – | – |
-400,000
| Closed | -$6.12M |
|
29
Corvus Pharmaceuticals
CRVS
$419M
| – | – |
-250,000
| Closed | -$603K |
|
|
30
CVRx
CVRX
$204M
| – | – |
-533,370
| Closed | -$6.52M |
|
|
31
Olema Pharmaceuticals
OLMA
$432M
| – | – |
-816,651
| Closed | -$7.64M |
|
|
KNTE
32
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| – | – |
-773,014
| Closed | -$13.7M |
|